EXACT Sciences Corporation

EXACT Sciences — Q4 2024 Earnings Presentation

19 slides from EXACT Sciences's earnings presentation, Feb 19, 2025

  1. Slide 1: Fourth-quarter 2024 earnings call

    Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Fourth-quarter 2024 earnings call February 19, 2025 EXACT SCIENCES 1

  2. Slide 2: Safe harbor and non-GAAP disclosures

    Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub

  3. Slide 3: Global leader in advanced cancer diagnostics with a differentiated platform

    Exact Sciences is a global leader in advanced cancer diagnostics with a differentiated platform OUR PEOPLE OUR IMPACT & SCALE OUR CAPABILITIES 7,000+ 4.6M Proprietary scientific platform detects cancer earlier and accurately team members test results in 2024 1,400+ $2.76B Powerful commercial engine,

  4. Slide 4: Core revenue grew 11% in 4Q24

    Core revenue grew 11% in 4Q24 Core revenue Screening revenue Precision Oncology revenue $715M $645M +11% $553M $487M +14% $160M $161M +0.4% 4Q23 4Q24 4Q23 4Q24 4Q23 4Q24 Please refer to our fourth-quarter 2024 earnings release at exactsciences.com for discussion of non-GAAP financial measures and re

  5. Slide 5: Profitability continued to improve in Q4, allowing investment in new product launches

    Profitability continued to improve in Q4, allowing investment in the launch of new products Adjusted EBITDA Adjusted EBITDA margin $75M 11% +52% ~300 bps $50M 8% 4Q23 4Q24 Please refer to our fourth-quarter 2024 earnings release at exactsciences.com for discussion of non-GAAP financial measures and

  6. Slide 6: 2024 was another year of profitable revenue growth

    2024 was another year of profitable revenue growth Core revenue Adjusted EBITDA Free cash flow Adjusted EBITDA margin $2.752B $323M $2.486B +11% 12% +48% $75M ~300 bps $219M 9% +133% $32M 2023 2024 2023 2024 2023 2024 Please refer to our fourth-quarter 2024 earnings release at exactsciences.com for

  7. Slide 7: 2025 guidance reflects double-digit growth and continued profit expansion

    2025 guidance reflects double-digit growth and continued profit expansion $ ∆ at % ∆ at 2024 2025 midpoint midpoint Total revenue $2.759B $3.025 – 3.085B +$296M +11% Screening $2.104B $2.350 - 2.390B +$266M +13% Precision Oncology $655M $675 - 695M +$30M +5% Adj. EBITDA $323M $410 - 440M +$102M +31%

  8. Slide 8: Cologuard is driving sustainable growth

    Cologuard® is driving sustainable growth Increasing Cologuard rescreen rates Engaging highest potential ordering providers Closing care gaps with payers and health systems Making Cologuard PlusTM the new standard of care Targeting younger people through new ads EXACT SCIENCES 8

  9. Slide 9: Expanding our global presence and launching new tests onto our oncology platform

    Expanding our global presence and launching new tests onto our oncology platform Patients tested in 2024 with Oncotype DX® Expanding Oncotype DX impact internationally Improving customer experience with ExactNexus Bringing Oncodetect to patients and providers Source: Exact Sciences internal data EXA

  10. Slide 10: Progress with Oncodetect and upcoming milestones

    Oncodetect uses unique science to predict and detect cancer relapses earlier Progress Progress Progress with with with Oncodetect Oncodetect multi-cancer early andupcoming and upcoming detection milestones and milestones upcoming milestones A positive Oncodetect Oncodetect patient is detects relapse

  11. Slide 11: Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment

    Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment EXACT SCIENCES 11

  12. Slide 12: EXACT SCIENCES

    EXACT SCIENCES 12

  13. Slide 13: Selected Unaudited Financial Information

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Revenue $ 713,424 $ 646,885 $ 2,758,867 $ 2,499,766 C

  14. Slide 14: Condensed Consolidated Balance Sheets

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Balance Sheets (Amounts in thousands) December 31, 2024 December 31, 2023 Assets Cash and cash equivalents $ 600,889 $ 605,378 Marketable securities 437,137 172,266 Accounts receivable, net 248,968 203,623 Inv

  15. Slide 15: U.S. GAAP to Non-GAAP Reconciliation: Core Revenue

    EXACT SCIENCES CORPORATION U.S. GAAP to Non-GAAP Reconciliation Core Revenue (Unaudited) (Amounts in thousands) GAAP Three Months Ended December 31, 2024 2023 % Change Screening $ 552,563 $ 486,706 14 % Precision Oncology 160,861 160,179 — % Total $ 713,424 $ 646,885 10 % Non-GAAP Three Months Ended

  16. Slide 16: U.S. GAAP to Non-GAAP Reconciliation: Adjusted EBITDA

    EXACT SCIENCES CORPORATION U.S. GAAP to Non-GAAP Reconciliation Adjusted EBITDA (Unaudited) (Amounts in thousands) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Net loss $ (864,585) $ (49,766) $ (1,028,857) $ (204,149) Interest expense (1) 9,577 7,865 27,016 19

  17. Slide 17: U.S. GAAP to Non-GAAP Reconciliations

    EXACT SCIENCES CORPORATION U.S. GAAP to Non-GAAP Reconciliations U.S. GAAP to Non-GAAP Measures (Unaudited) (Amounts in thousands) Three Months Ended December 31, 2024 Research & General & Development Sales & Marketing Administrative Loss from Income Tax Benefit Gross Profit Expenses Expenses Expens

  18. Slide 18: U.S. GAAP to Non-GAAP Reconciliation

    EXACT SCIENCES CORPORATION U.S. GAAP to Non-GAAP Reconciliation U.S. GAAP to Non-GAAP Measures (Unaudited) (Amounts in thousands) Three Months Ended December 31, 2023 Research & General & Development Sales & Marketing Administrative Loss from Income Tax Benefit Gross Profit Expenses Expenses Expense

  19. Slide 19: U.S. GAAP to Non-GAAP Reconciliation: Operating Cash Flow to Free Cash Flow

    EXACT SCIENCES CORPORATION U.S. GAAP to Non-GAAP Reconciliation Operating Cash Flow to Free Cash Flow (Unaudited) (Amounts in thousands) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Net cash provided by operating activities $ 47,063 $ 69,549 $ 210,536 $ 156,11

Exact Sciences — Q4 2024 Earnings Presentation on 6ix